FHI
Federated Hermes, Inc.
FHI has slightly lower modeled downside risk, despite its lower overall score.
MS
Morgan Stanley
MS has the edge over FHI overall, supported by stronger fundamentals and stronger modeled upside.
FHI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
FHI's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like FHI.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
FHI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.5x | $52.45 | -17% |
| Fair | 11x | $62.14 | -2.2% |
| Current | 11x | $63.52 | — |
| Forward | 11x | $63.52 | — |
| Expensive | 13x | $71.76 | +13% |
Historical ranges are pointers, not guarantees.
FHI has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
FHI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for FHI, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
FHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.89 | +6.6% |
| Q3 2026 | $5.53 | +14% |
| Q2 2026 | $5.37 | +18% |
| Q1 2026 | $5.15 | +43% |
| Q4 2025 | $5.13 | +59% |
| Q3 2025 | $4.83 | +56% |
| Q2 2025 | $4.55 | +57% |
| Q1 2025 | $3.59 | +2.3% |
| Q4 2024 | $3.23 | -5% |
FHI earned $5.53 per share over the past year, up 14% from the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over FHI on earnings, with more consistent year-over-year improvement.
FHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $507.3M | +8.1% |
| Q2 2026 | $502.8M | +18% |
| Q1 2026 | $479M | +13% |
| Q4 2025 | $482.8M | +14% |
| Q3 2025 | $469.4M | +15% |
| Q2 2025 | $424.8M | +5.5% |
| Q1 2025 | $423.5M | +6.9% |
| Q4 2024 | $424.7M | +8.5% |
FHI's revenue has grown year over year for nine quarters in a row: $507M last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +2.6 points |
| Q2 2026 | 26% | -1.1 points |
| Q1 2026 | 26% | -4.7 points |
| Q4 2025 | 28% | +2.1 points |
| Q3 2025 | 28% | +0.2 points |
| Q2 2025 | 28% | +17 points |
| Q1 2025 | 31% | +6.2 points |
| Q4 2024 | 26% | -0.2 points |
FHI's operating margin was 30% last quarter, up 2.6 points from the same quarter a year ago.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over FHI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over FHI on profitability, with a higher operating margin.
FHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $120.2M | +18% |
| Q2 2026 | $79.7M | +343% |
| Q1 2026 | $24M | +80% |
| Q4 2025 | $161.6M | +28% |
| Q3 2025 | $101.6M | -15% |
| Q2 2025 | $18M | -78% |
| Q1 2025 | $13.3M | -1% |
| Q4 2024 | $126.2M | -1% |
FHI has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
FHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -950K shares |
| 1 year | -4.1% | -3.1M shares |
| 3 years | -15% | -12.7M shares |
| 5 years | -24% | -22.3M shares |
| Available history | -27% | -26.3M shares |
FHI has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $57.4M |
| Q2 2026 | $64M |
| Q1 2026 | $64.7M |
| Q4 2025 | $77.1M |
| Q3 2025 | $21,000 |
| Q2 2025 | $65.5M |
| Q1 2025 | $120.1M |
| Q4 2024 | $23.4M |
FHI spent $263M buying back its own shares over the past year, up 26% from the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
FHI Net Leverage
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
FHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.8 | Neutral |
| Stochastic | 60.5 | Neutral |
FHI's weekly RSI is 62 (neutral) and its Stochastic is 60 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
FHI PE vs Financial Services Sector
| Metric | FHI | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 12% below |
| PE % | 55 | 63 | 8 pts below |
FHI has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
FHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.6 | 8.3% above |
| 20 week MA | $59.8 | 6.2% above |
| 50 week MA | $57.0 | 11% above |
| 100 week MA | $50.8 | 25% above |
| 200 week MA | $43.4 | 46% above |
FHI has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
FHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.7 | $28.5 | -13% |
| 2021 | $28.5 | $37.4 | +31% |
| 2022 | $37.4 | $35.7 | -4.4% |
| 2023 | $35.7 | $33.9 | -5.2% |
| 2024 | $33.9 | $41.4 | +22% |
| 2025 | $41.4 | $54.1 | +31% |
| 2026 YTD | $54.1 | $63.5 | +17% |
FHI has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.